U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H28N4O3.ClH
Molecular Weight 432.9444
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETONITAZENE HYDROCHLORIDE

SMILES

CCN(CC)CCn1c2ccc(cc2nc1Cc3ccc(cc3)OCC)N(=O)=O.Cl

InChI

InChIKey=JTBRYBUIGVMMQL-UHFFFAOYSA-N
InChI=1S/C22H28N4O3.ClH/c1-4-24(5-2)13-14-25-21-12-9-18(26(27)28)16-20(21)23-22(25)15-17-7-10-19(11-8-17)29-6-3;/h7-12,16H,4-6,13-15H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula C22H28N4O3
Molecular Weight 396.4836
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Etonitazene is a potent and selective mu-opioid agonist. It was developed in CIBA. Administration of etonitazene may induce respiratory depression, and therefor etonitazene is not used in humans. Etonitazene is explicitly listed as an illegal drug under UN convention and is illegal throughout the world.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.5 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effects of etonitazene upon respiratory neurons.
1967 Jan 15
Photoactivatable opiate derivatives as irreversible probes of the mu-opioid receptor.
1990 Sep
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
1998 Mar
Intravenous self-administration of etonitazene alone and combined with cocaine in rhesus monkeys: comparison with heroin and antagonism by naltrexone and naloxonazine.
2009 Jun
Analgesic tolerance to high-efficacy agonists but not to morphine is diminished in phosphorylation-deficient S375A μ-opioid receptor knock-in mice.
2011 Sep 28
Patents

Sample Use Guides

In rat tail-withdrawal assay, etonitazene was administered subcutaneously. ED50 was 0.38 mg/kg.
Route of Administration: Other
In Vitro Use Guide
Binding of etonitazene to mu-opioid receptors from the membrane fraction of rat brains (minus cerebellum) was studied using [3H]DAMGO as a radioligand. Etonitazene binds to mu-opioid receptors with Ki of 0.5 nM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:09:06 UTC 2021
Edited
by admin
on Sat Jun 26 10:09:06 UTC 2021
Record UNII
LD057W8P8B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETONITAZENE HYDROCHLORIDE
MI  
Common Name English
1H-BENZIMIDAZOLE-1-ETHANAMINE, 2-((4-ETHOXYPHENYL)METHYL)-N,N-DIETHYL-5-NITRO-, MONOHYDROCHLORIDE
Common Name English
ETONITAZENE HYDROCHLORIDE [MI]
Common Name English
2-((4-ETHOXYPHENYL)METHYL)-N,N-DIETHYL-5-NITRO-1H-BENZIMIDAZOLE-1-ETHANAMINE HYDROCHLORIDE
Systematic Name English
C-20684
Code English
BENZIMIDAZOLE, 1-(2-(DIETHYLAMINO)ETHYL)-2-(P-ETHOXYBENZYL)-5-NITRO-, HYDROCHLORIDE
Common Name English
Code System Code Type Description
CAS
2053-25-0
Created by admin on Sat Jun 26 10:09:06 UTC 2021 , Edited by admin on Sat Jun 26 10:09:06 UTC 2021
PRIMARY
FDA UNII
LD057W8P8B
Created by admin on Sat Jun 26 10:09:06 UTC 2021 , Edited by admin on Sat Jun 26 10:09:06 UTC 2021
PRIMARY
PUBCHEM
16334
Created by admin on Sat Jun 26 10:09:06 UTC 2021 , Edited by admin on Sat Jun 26 10:09:06 UTC 2021
PRIMARY
EPA CompTox
2053-25-0
Created by admin on Sat Jun 26 10:09:06 UTC 2021 , Edited by admin on Sat Jun 26 10:09:06 UTC 2021
PRIMARY
MERCK INDEX
M5197
Created by admin on Sat Jun 26 10:09:06 UTC 2021 , Edited by admin on Sat Jun 26 10:09:06 UTC 2021
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE